Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the ...

"The winners in life are differentiated from the losers in life because the winners never fall," Albert Bourla says. "The ...

Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...

Pfizer's COVID Vaccine for Kids Under 5 , Moves Closer to FDA Approval . Pfizer announced on June 1 that its application to the Food and Drug Administration (FDA) for the vaccine was complete. Pfizer ...

The U.S. Food and Drug Administration will decide on full approval of the Pfizer-BioNTech COVID-19 vaccine by January 2022. Pfizer announced on Friday that the FDA granted their request for primary ...

The U.S. Food and Drug Administration issued its full approval of the Pfizer covid-19 vaccine Monday. The move comes eight months after the Pfizer vaccine was authorized for emergency use in the ...

Dr. Albert Bourla became Pfizer’s CEO months before the COVID-19 pandemic took hold of the US. Under his leadership, Pfizer manufactured 3 billion doses of the first FDA-approved vaccine in the first ...